e-ISSN: Pending
Replication FailureOpen accessDiseases of the digestive system. Gastroenterology

Ten-day vonoprazan–amoxicillin dual therapy versus 14-day esomeprazole–amoxicillin dual therapy for first-line eradication: a prospective multicenter randomized controlled trial

Ben-Gang Zhou; Ming-Wen Guo; Li-Juan Zhang; Zhi-Dong Liu; Chun-Hua Liu; Xue-Feng Li; Shun-Song Li; Peng Xiao · 2024 · Therapeutic Advances in Gastroenterology

WASTE classifies this as Replication Failure · AI classification, approximate

A previously reported effect did not replicate here — verify it holds before you build on it.

Abstract

Background: The efficacy of the 14-day esomeprazole–amoxicillin (EA) dual therapy in eradicating Helicobacter pylori ( H. pylori ) has been widely discussed previously. Vonoprazan, a novel potassium-competitive acid blocker, presents rapid, potent, and long-lasting acid inhibitory effects compared to esomeprazole. However, there is currently a scarcity of direct comparisons between the 10-day vonoprazan–amoxicillin (VA) and the 14-day EA dual therapy for H. pylori eradication. Objectives: This study aimed to compare the efficacy and safety of the 10-day VA and the 14-day EA dual therapy for H.

Abstract by Ben-Gang Zhou; Ming-Wen Guo; Li-Juan Zhang; Zhi-Dong Liu; Chun-Hua Liu; Xue-Feng Li; Shun-Song Li; Peng Xiao, Therapeutic Advances in Gastroenterology (2024) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: DOAJ · DOI 10.1177/17562848241309870